Additionally, thrombophilia screening (including Factor V Leiden, prothrombin gene mutation, protein C/S, and antithrombin III levels) was not completed during the acute phase but remains an important consideration in evaluating stroke in the young. This evidence concerns the gene F5 and Rare hereditary thrombophilia.